Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Blood Adv. 2023 Nov 14;7(21):6441-6450. doi: 10.1182/bloodadvances.2023009847.
Blood Adv. 2023.
PMID: 37581981
Free PMC article.
Clinical Trial.
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
Vichinsky E, El-Beshlawy A, Al Zoebie A, Kamdem A, Koussa S, Chotsampancharoen T, Bruederle A, Gilotti G, Han J, Elalfy M.
Vichinsky E, et al. Among authors: gilotti g.
Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26507. Epub 2017 Mar 10.
Pediatr Blood Cancer. 2017.
PMID: 28296163
Item in Clipboard
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M.
Passamonti F, et al. Among authors: gilotti g.
Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18.
Lancet Haematol. 2022.
PMID: 35597252
Clinical Trial.
Item in Clipboard
International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
El-Beshlawy A, Inusa B, Beneitez Pastor D, Xicoy B, Soledada Duran Nieto M, Bruederle A, Azmon A, Gilotti G, Elalfy M.
El-Beshlawy A, et al. Among authors: gilotti g.
Hematology. 2019 Dec;24(1):238-246. doi: 10.1080/16078454.2018.1558758.
Hematology. 2019.
PMID: 30558524
Free article.
Clinical Trial.
Item in Clipboard
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK.
Cervantes F, et al. Among authors: gilotti g.
Leukemia. 2021 Dec;35(12):3455-3465. doi: 10.1038/s41375-021-01261-x. Epub 2021 May 20.
Leukemia. 2021.
PMID: 34017073
Free PMC article.
Clinical Trial.
Item in Clipboard
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK.
Cervantes F, et al. Among authors: gilotti g.
Leukemia. 2021 Dec;35(12):3626. doi: 10.1038/s41375-021-01396-x.
Leukemia. 2021.
PMID: 34475521
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite